comprehensive -WSS

comprehensive

author：fashion 2025-08-28 08:40:25 - browse：78

Feng Zhang Editas — Aera was formed to pursue a nanoparticle described by Feng Zhang in 2021. Susan Walsh/AP

Aera Therapeutics, a startup launched by the CRISPR pioneer Feng Zhang last year to solve one of the biggest bottlenecks in genetic medicine, has laid off a quarter of its staff, the company confirmed to STAT.

The layoffs come as the biotech market remains mired in a now nearly three-year-long downturn that has left startups struggling to attract both private and public funds. Aera attributed the layoffs to those headwinds and indicated it had axed a portion of the company dedicated to developing new gene-editing enzymes.

“In 2023, Aera launched to pursue an ambitious mission to develop transformative genetic medicines by harnessing enabling delivery technologies and precision payloads,” spokesman Dan Budwick said in a statement. “Although Aera remains in a strong cash position today, given the current biotech funding environment, we have chosen to take steps to focus our strategy and investments on the development of our novel delivery platforms, thereby further extending our cash runway.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： PBM executives asked to testify by House panel

Wikipedia

WSS

U.K. Biobank has 500,000 peoples' genome sequences available

Welsh Carson private equity firm escapes from FTC antitrust case

What don’t we know about an Alzheimer’s drug side effect?

How to pay for weight loss drugs and save Medicare

HHS's proposed rule does nothing to address the climate crisis

Rep. Raul Ruiz on the physician shortage and more

explore

comprehensive

hotspot

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Brain MRIs reveal impact of 'toxic stress' on Black children

Psychedelics group wrestles with new pharma identity

Disappointing trial forces Pfizer to pivot on obesity medicine plans

BioMarin wins approval for gene therapy to treat hemophilia A

Takeda, Janssen join wearable maker to measure scratching

Drug repurposing or repositioning? The language matters

With clinical trial data readouts, here's how to spot spin

Moonlake's readout produced a cash windfall. Risks remain

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

hotspot

The EPA's new lead rule: How one expert crunched the numbers

Can gargling with Listerine treat gonorrhea of the mouth?

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

Can gargling with Listerine treat gonorrhea of the mouth?

Rep. Raul Ruiz on the physician shortage and more

Brain technologies pose threats that are all too real, experts warn

Wikipedia

Wikipedia

hotspot

hotspot